Status:

SUSPENDED

Safety and Efficacy Study of the PTMA Device to Reduce Mitral Valve Regurgitation in Patients With Heart Failure

Lead Sponsor:

Viacor

Collaborating Sponsors:

Duke University

Medifacts International Corporation

Conditions:

Mitral Regurgitation

Heart Failure

Eligibility:

All Genders

50+ years

Phase:

PHASE2

PHASE3

Brief Summary

Improvement in heart failure with moderate to severe mitral regurgitation using a percutaneously delivered implantable device residing in the coronary sinus

Detailed Description

Device under Test: The Viacor® Percutaneous Transvenous Mitral Annuloplasty (PTMA) system comprises a sterile implantable cardiac device and associated custom accessories to assist implantation. The P...

Eligibility Criteria

Inclusion

  • Patient has moderate functional MR: regurgitant orifice area \>/= 0.20cm2 or regurgitant volume \>/= 30 mL/beat or regurgitant fraction \>/= 30%
  • Symptomatic heart failure NYHA Class II to IV
  • LV dysfunction (25% \< LVEF \< 50% by echocardiography) OR dilated mitral annulus \> 30mm

Exclusion

  • MR of organic origin
  • Severe mitral leaflet tethering
  • History of MI or PCI within 60 days of study procedure
  • Inability to walk a minimum of 100 meters in 6 minutes
  • Significant left main stenosis or proximal circumflex stent
  • Indication of non-patent CSO or discontinuous CS-GCV-AIV
  • Bi-ventricular with leads in CS or other devices impeding device placement
  • Severe aortic valvular disease
  • Chronic corticosteroid use other than \< 20mg prednisone for arthritis
  • Significant co-morbidities

Key Trial Info

Start Date :

February 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2015

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT00815386

Start Date

February 1 2009

End Date

December 1 2015

Last Update

February 14 2011

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

University of Ottawa Heart Institute

Ottawa, Ontario, Canada, K1Y 4W7

2

Royal Victoria Hospital, McGill University Medical Center

Montreal, Quebec, Canada, H3A1A1

3

Laval Hospital, Quebec Heart-Lung Institute

Québec, Quebec, Canada, G1V4G5